We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00423748
Recruitment Status : Completed
First Posted : January 18, 2007
Last Update Posted : April 16, 2009
Information provided by:
Gilead Sciences

Brief Summary:
A phase 3, randomized, double-blind, placebo-controlled study to assess safety and efficacy of ambrisentan in subjects with pulmonary arterial hypertension.

Condition or disease Intervention/treatment Phase
Pulmonary Arterial Hypertension Drug: ambrisentan Phase 3

Detailed Description:
Subjects in these randomized studies will receive one of two doses of ambrisentan or placebo. Inclusion is not based on a specified WHO functional classification. Rather, subjects with WHO Class I-IV symptoms are eligible if their 6-minute walk distance is 150-450 meters and they meet the study-specified hemodynamic criteria. Subjects with anorexigen or HIV infection related PAH are eligible but subjects with congenital heart disease and pediatric subjects are excluded. The study requires a historical cardiac catheterization and other diagnostic procedures.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 186 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Ambrisentan in PAH - A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Study of Ambrisentan in Subjects With Pulmonary Arterial Hypertension
Study Start Date : December 2003
Study Completion Date : February 2006

Primary Outcome Measures :
  1. Change from baseline in the six-minute walk distance evaluated after 12 weeks of therapy compared to placebo.

Secondary Outcome Measures :
  1. Change from baseline measured after 12 weeks of treatment compared to placebo in the Borg Dyspnea Index; WHO Functional Classification; and the SF-36 Health Survey.
  2. Clinical worsening of PAH.
  3. Assessment of the safety and tolerability of the study drug.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 18 years of age or order
  • Current diagnosis of either PPH orPAH secondary to the scleroderma spectrum of disease, systemic lupus erythematosus, anorexigen use, or HIV infection at the Screening Visit
  • Right heart catheterization, completed prior to Screening Visit must meet pre-specified hemodynamic criteria
  • Female subjects of childbearing potential must have a negative serum pregnancy test and must agree to use a reliable double barrier method of contraception until study completion and for at least four weeks following their final study visit
  • Male subjects must be informed of the potential risks of testicular tubular atrophy and infertility associated with taking this study drug and queried regarding his understanding of the potential risks as described in the Informed Consent Form

Exclusion Criteria:

  • PAH due to or associated with congenital heart disease, coronary artery disease, left heart disease, interstitial lung disease, chronic obstructive pulmonary disease, veno-occlusive disease, chronic thrombotic and/or embolic disease, or sleep apnea
  • Portopulmonary hypertension
  • Bosentan within four weeks prior to Screening
  • Phosphodiesterase type V inhibitor or chronic prostanoid therapy within four weeks prior to Screening
  • IV inotrope use within two weeks prior to Screening
  • ALT or AST lab value that is greater than 1.5 times the upper limit of normal
  • Pulmonary function tests not meeting pre-specified criteria
  • Contraindication to treatment with an ERA
  • History of malignancies other than basal cell carcinoma of the skin or in situ carcinoma of the cervix within the past five years
  • Females who are pregnant or breastfeeding
Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00423748    
Other Study ID Numbers: AMB-320
First Posted: January 18, 2007    Key Record Dates
Last Update Posted: April 16, 2009
Last Verified: April 2009
Additional relevant MeSH terms:
Layout table for MeSH terms
Pulmonary Arterial Hypertension
Familial Primary Pulmonary Hypertension
Vascular Diseases
Cardiovascular Diseases
Hypertension, Pulmonary
Lung Diseases
Respiratory Tract Diseases
Antihypertensive Agents